Prototype Vaccine Protects Against Multiple Chlamydia Strains
By LabMedica International staff writers Posted on 03 Aug 2016 |
Image: A photomicrograph (200X) showing McCoy cell monolayers with Chlamydia trachomatis inclusion bodies (Photo courtesy of the CDC).
A prototype vaccine to protect against Chlamydia trachomatis infection gave promising results when tested in vitro and in a mouse model system.
C. trachomatis infections in women are often asymptomatic and, if left untreated, can lead to significant complications including pelvic inflammatory disease and tubal factor infertility. Vaccine development efforts over the past 30 years have been unproductive, and currently there is no vaccine approved for use in humans.
There are several serologically distinct strains or serovars of C. trachomatis, which means that any potential vaccine would need to provide protection against multiple serovars. To accomplish this task, investigators at McMaster University (Hamilton, ON, Canada) based their vaccine on the components of a highly conserved type III secretion system (T3SS) composed of both structural and effector proteins, which is an essential virulence factor for infection and intracellular replication.
In the current study they evaluated a novel fusion protein antigen (BD584), which consisted of three T3SS proteins from C. trachomatis (CopB, CopD, and CT584) as a potential chlamydial vaccine candidate.
The investigators reported in the June 17, 2016, online edition of the journal Vaccine that intranasal immunization with BD584 elicited serum-neutralizing antibodies that inhibited C. trachomatis infection in vitro. Following intravaginal challenge with C. muridarum, immunized mice had a 95% reduction in chlamydial shedding from the vagina at the peak of infection and cleared the infection sooner than control mice. Immunization with BD584 also reduced the rate of hydrosalpinx (distally blocked fallopian tubes filled with serous or clear fluid) by 87.5% compared to control mice.
These results suggested that highly conserved proteins of the chlamydial T3SS may represent good candidates for a Chlamydia vaccine.
“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said first author Dr. David Bulir, a researcher at McMaster University. “Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”
Related Links:
McMaster University
C. trachomatis infections in women are often asymptomatic and, if left untreated, can lead to significant complications including pelvic inflammatory disease and tubal factor infertility. Vaccine development efforts over the past 30 years have been unproductive, and currently there is no vaccine approved for use in humans.
There are several serologically distinct strains or serovars of C. trachomatis, which means that any potential vaccine would need to provide protection against multiple serovars. To accomplish this task, investigators at McMaster University (Hamilton, ON, Canada) based their vaccine on the components of a highly conserved type III secretion system (T3SS) composed of both structural and effector proteins, which is an essential virulence factor for infection and intracellular replication.
In the current study they evaluated a novel fusion protein antigen (BD584), which consisted of three T3SS proteins from C. trachomatis (CopB, CopD, and CT584) as a potential chlamydial vaccine candidate.
The investigators reported in the June 17, 2016, online edition of the journal Vaccine that intranasal immunization with BD584 elicited serum-neutralizing antibodies that inhibited C. trachomatis infection in vitro. Following intravaginal challenge with C. muridarum, immunized mice had a 95% reduction in chlamydial shedding from the vagina at the peak of infection and cleared the infection sooner than control mice. Immunization with BD584 also reduced the rate of hydrosalpinx (distally blocked fallopian tubes filled with serous or clear fluid) by 87.5% compared to control mice.
These results suggested that highly conserved proteins of the chlamydial T3SS may represent good candidates for a Chlamydia vaccine.
“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said first author Dr. David Bulir, a researcher at McMaster University. “Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”
Related Links:
McMaster University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples